Advertisement

Ads Placeholder
Loading...

Bristol-Myers Squibb Company PFD CONV 2

BMYMPPNK
Healthcare
Drug Manufacturers - General
$400.00
$-540.22(-57.46%)
U.S. Market is Open • 15:46

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Stock Forecast & Price Predictions

Get the latest Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) stock forecast across short-term and long-term horizons. Meyka AI generates price predictions using advanced models trained on historical data. These forecasts are not investment advice but directional insights to help investors and traders plan strategies.

Model Information

The Forecast Prediction Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full Disclaimer

Monthly Forecast

Predicted Price$1185.24
Change↑ $785.24 (196.31%)

Quarterly Forecast

Predicted Price$772.77
Change↑ $372.77 (93.19%)

Yearly Forecast

Predicted Price$693.12
Change↑ $293.12 (73.28%)

3 Years Forecast

Predicted Price$460.16
Change↑ $60.16 (15.04%)

5 Years Forecast

Predicted Price$222.11
Change↓ $-177.89 (-44.47%)

7 Years Forecast

Predicted Price$0.00
Change↓ $-400.00 (-100.00%)

Bristol-Myers Squibb Company PFD CONV 2 Stock Forecast Summary

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) stock is currently priced at $400.00. Based on Meyka AI predictions, the short-term outlook is bullish, with momentum pointing higher. The 1-month projection suggests a move toward $1185.24.

In the long term, BMYMP shows a bullish trend. The 2027 forecast points to $693.12 (73.28% change), while the 2031 forecast suggests $222.11 (-44.47% change). Looking 7 years ahead, projections estimate the stock could trade near $0.00, a -100.00% change from today’s price.

Overall Sentiment

Bullish

Short-Term Outlook

Bullish

Long-Term Outlook

Bullish

This mix indicates that Bristol-Myers Squibb Company PFD CONV 2 stock is expected to rise steadily over the coming years.

Investment Calculator

Estimate your potential returns on BMYMP based on our AI price forecasts. Enter your investment amount and select a target date.

Based on your investment of $1,000.00 in Bristol-Myers Squibb Company PFD CONV 2 and holding until April 6th, 2027, you could make a potential +$732.80 profit, reflecting a +73.3% ROI over the next 365 days.

$

$Shares Bought

2.5000

@ $400.00/share

~Forecast Price

$693.12

1-year AI forecast

$Est. Portfolio Value

$1,732.80

+$732.80 profit

%ROI

+73.3%

return on investment

Bristol-Myers Squibb Company PFD CONV 2 yearly Price Forecast Chart

Explore the yearly forecast chart for BMYMP, which maps expected price movement, support levels, and resistance targets. The dropdown lets you view forecasts across multiple horizons, from short-term daily trends to 7-year projections, helping investors evaluate Bristol-Myers Squibb Company PFD CONV 2 over different timeframes.

No forecast data available

No prediction data found for this time period.

empty-state-iconForecasting data is not available for BMYMPForecasting details for BMYMP are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Bristol-Myers Squibb Company PFD CONV 2 Stock Forecast 2026

The forecast for Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) in 2026 suggests a price of $693.12, representing a 73.28% move from today’s price.

Average Target: $693.12

Market Outlook: bullish based on current trend indicators.

Key Drivers in 2026:
  • Earnings growth projections.
  • Competitive performance in the Healthcare.
  • Macroeconomic factors such as interest rates and inflation.

Bristol-Myers Squibb Company PFD CONV 2 Stock Forecast 2030

By 2030, Meyka AI projects BMYMP could trade near $222.11, showing a potential -44.47% compared to current levels.

Average Target: $222.11

Market Outlook: bearish.

What could influence the 2030 forecast:
  • Technological innovation and product cycles.
  • Expansion into global markets.
  • Long-term investor sentiment toward Bristol-Myers Squibb Company PFD CONV 2.

Frequently Asked Questions